Stories
Slash Boxes
Comments

SoylentNews is people

posted by Fnord666 on Friday July 24 2020, @03:58PM   Printer-friendly
from the packaged-for-ease-of-handling dept.

Lab-made virus infects cells, interacts with antibodies just like SARS-CoV-2:

Airborne and potentially deadly, the virus that causes COVID-19 can only be studied safely under high-level biosafety conditions. Scientists handling the infectious virus must wear full-body biohazard suits with pressurized respirators, and work inside laboratories with multiple containment levels and specialized ventilation systems. While necessary to protect laboratory workers, these safety precautions slow down efforts to find drugs and vaccines for COVID-19 since many scientists lack access to the required biosafety facilities.

To help remedy that, researchers at Washington University School of Medicine in St. Louis have developed a hybrid virus that will enable more scientists to enter the fight against the pandemic. The researchers genetically modified a mild virus by swapping one of its genes for one from SARS-CoV-2, the virus that causes COVID-19. The resulting hybrid virus infects cells and is recognized by antibodies just like SARS-CoV-2, but can be handled under ordinary laboratory safety conditions.

The study is available online in Cell Host & Microbe.

I've never had this many requests for a scientific material in such a short period of time. We've distributed the virus to researchers in Argentina, Brazil, Mexico, Canada and, of course, all over the U.S. We have requests pending from the U.K. and Germany. Even before we published, people heard that we were working on this and started requesting the material."

Sean Whelan, PhD, co-senior author, the Marvin A. Brennecke Distinguished Professor and head of the Department of Molecular Microbiology

[...] Since the hybrid virus looks like SARS-CoV-2 to the immune system but does not cause severe disease, it is a potential vaccine candidate, Diamond added. He, Whelan and colleagues are conducting animal studies to evaluate the possibility.

Journal Reference:
Case, J.B., et al. (2020) Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host & Microbe. doi.org/10.1016/j.chom.2020.06.021.


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0) by Anonymous Coward on Saturday July 25 2020, @05:44PM

    by Anonymous Coward on Saturday July 25 2020, @05:44PM (#1026199)

    Mmmm - you're making me hungry. Think I'll go drive up and down the highway, and see what's on the menu.